Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes

Raffaele Marfella (), Celestino Sardu, Nunzia D’Onofrio, Francesco Prattichizzo, Lucia Scisciola, Vincenzo Messina, Rosalba La Grotta, Maria Luisa Balestrieri, Paolo Maggi, Claudio Napoli, Antonio Ceriello () and Giuseppe Paolisso
Additional contact information
Raffaele Marfella: Università degli Studi della Campania “Luigi Vanvitelli”
Celestino Sardu: Università degli Studi della Campania “Luigi Vanvitelli”
Nunzia D’Onofrio: Università degli Studi della Campania “Luigi Vanvitelli”
Francesco Prattichizzo: IRCCS MultiMedica
Lucia Scisciola: Università degli Studi della Campania “Luigi Vanvitelli”
Vincenzo Messina: Sant’Anna Hospital
Rosalba La Grotta: IRCCS MultiMedica
Maria Luisa Balestrieri: Università degli Studi della Campania “Luigi Vanvitelli”
Paolo Maggi: Università degli Studi della Campania “Luigi Vanvitelli”
Claudio Napoli: Università degli Studi della Campania “Luigi Vanvitelli”
Antonio Ceriello: IRCCS MultiMedica
Giuseppe Paolisso: Università degli Studi della Campania “Luigi Vanvitelli”

Nature Communications, 2022, vol. 13, issue 1, 1-7

Abstract: Abstract Patients with type 2 diabetes (T2D) are characterized by blunted immune responses, which are affected by glycaemic control. Whether glycaemic control influences the response to COVID-19 vaccines and the incidence of SARS-CoV-2 breakthrough infections is unknown. Here we show that poor glycaemic control, assessed as mean HbA1c in the post-vaccination period, is associated with lower immune responses and an increased incidence of SARS-CoV-2 breakthrough infections in T2D patients vaccinated with mRNA-BNT162b2. We report data from a prospective observational study enroling healthcare and educator workers with T2D receiving the mRNA-BNT162b2 vaccine in Campania (Italy) and followed for one year (5 visits, follow-up 346 ± 49 days) after one full vaccination cycle. Considering the 494 subjects completing the study, patients with good glycaemic control (HbA1c one-year mean

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-30068-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30068-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-30068-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().